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Abstract 
Background: To compare the intra-operative 
analgesic benefit of cataract surgery under topical 
anesthesia with and without pre-operative NSAIDs, 
namely nepafenac 0.1% (Alcon Laboratories Inc, 
Nevanec®, Fort Worth, TX, USA) 
Method: In a study carried out at Mater Dei 
Hospital, Ophthalmic department, Malta, 199 
patients with a cataract were divided into two 
groups. 100 eyes received nepafenac 0.1% pre-
operatively while 99 eyes did not. Intra-operative 
discomfort was judged by assessing facial 
grimacing, restlessness, irritability and distress and 
the results were noted. Patients were divided into 
refractive error groups, namely myopic, 
hypermetropic and emmetropic.  
Results: Pre-operative nepafenac 0.1% 
produced significantly more pain free cataract 
surgeries, resulting in a discomfort rate of 9% vs 
28% in the group where pre-operative nepafenac 
0.1% was not used. Pain was also most evidently 
observed on insertion of the phaco handpiece. This 
may be said for patients in all refractive errors 
groups. 
Conclusions: The analgesic efficacy of 
nepafenac 0.1% pre-operatively is significant in 
reduced intra-operative discomfort during cataract 
surgery repair under topical analgesia.   
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Introduction 
Nepafenac 0.1% (Alcon Laboratories Inc, 
Nevanac®, Fort Worth, TX, USA) is an ophthalmic 
NSAID. It has a prodrug structure, making it a 
neutral molecule. This property allows it to 
penetrate the cornea, after which it is converted by 
intraocular hydrolases to its more active moiety 
amfenac.1 Nepafenac is unique, in that its 
bioconversion to amfenac is targeted to the iris and 
ciliary body and, to an even greater extent, the 
retina and choroid.  
Like other NSAIDs, nepafenac works by 
inhibiting the synthesis of prostaglandins. While we 
are aware of the beneficial implications of NSAIDs 
in reducing post-operative inflammation and its 
sequelae such as cystoid macular oedema, not much 
is yet known about how pre-operative NSAIDs 
possibly have an effect in reducing intra-operative 
discomfort.  
The primary objective of this study was to 
assess the effect of pre-operative nepafenac 0.1% 
on the effects of intra-operative discomfort in 
cataract surgery performed under local anaesthetic. 
Secondary outcomes included defining the stage at 
which discomfort was most likely to be experienced 
and the impact of refractive error on the degree of 
discomfort experienced.  
 
Materials and Methods 
This observational study was performed at 
Mater Dei Hospital Malta between January 2014 
and January 2016. The study included 196 patients 
(199 eyes) who underwent phacoemulsification 
surgery by the same consultant surgeon. 100 eyes 
were operated on after application of pre-operative 
topical anesthesia using oxybuprocaine 0.4% while 
99 eyes were operated on after application of pre-
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operative oxybuprocaine 0.4% and nepafenac 0.1%. 
All procedures were performed by the same 
consultant surgeon.  
The study was approved by the appropriate 
patient safety and ethics approval boards. All 
patients underwent an extensive pre-operative 
assessment.  
Strict inclusion and exclusion criteria were 
established. Patients being unfit for surgery were 
excluded from the study cohort. Patients with 
contra-indications to non-steroidal anti- 
inflammatory medication or who were already on 
regular pain relief were not considered for the 
purpose of the study. Patients, who had 
communication problems, were unable to co-
operate during pre-operative assessment or who 
were deemed excessively photophobic or expected 
to endure excessive discomfort due to prolonged 
surgery or pupils which were difficult to dilate were 
excluded from the study, necessitating surgery 
under general anesthesia. 
All patients were advised on the steps of the 
procedure, the expected duration and the 
importance of relaxing throughout the procedure. 
Patients were advised to keep their eyes open 
throughout the procedure, avoiding excessive eye 
movement at all times. Patients were consented 
before the procedure and all patients who failed to 
provide their consent were excluded from the study.  
All patients were brought in the morning of 
the procedure. 100 eyes were instilled with 2 drops 
of oxybuprocaine 0.4% 5 minutes before the 
procedure. 99 eyes were also given 2 drops of 
nepafenac 0.1% 1 hour before the procedure. 
Patients who were excessively anxious or suffered 
severe pain during the procedure were given 
retrobulbar blocks. Top-up topical anaesthetic was 
also used. Such patients were considered as clear 
failures to the success of both pre-operative 
nepafenac 0.1% and oxybuprocaine0.4%. No effort 
was made to randomize the pre-operative nepafenac 
0.1% group from the group that did not receive such 
NSAIDs.  
All procedures were performed by the same 
consultant ophthalmic surgeon. The Infinity 
Phacoemulsification Machine by Alcon was used 
throughout the study. Patients underwent the same 
three stage approach; capsulorrhexis, 
hydrodissection and phacoemulsification, followed 
by IOL insertion. An effort was made to maintain 
the same size of main incision whilst also making 
use of the same phaco pressures as these may 
influence the discomfort experienced. Foldable 
posterior chamber intra-ocular lenses by Alcon 
were used.  
Intra-operative and post-operative discomfort 
was assessed by the same consultant surgeon. 
Verbal response, restlessness and facial grimacing 
observed were used to identify any discomfort. An 
official pain score scale by patients was not utilized 
in order to avoid patient variability and bias.  
Results 
A total of 199 eyes were used for this study. 
Only patients who completed the surgery without 
intra-operative complications were deemed fit to be 
included in the study.  
The mean age of patients used in the study 
was 76 years, with ages ranging from 32 years to 90 
years of age. Over 95% of patients were Caucasian. 
108 of the eyes belonged to female patients and 91 
belonged to male patients. There was no significant 
difference in the degree of discomfort witnessed 
between male and female patients.  
Discomfort was witnessed in 28% of patients 
who were not provided with pre-operative 
nepafenac 0.1% but in only 9% of patients to whom 
nepafenac 0.1% was given pre-operatively (Figures 
1-3). By using Fisher’s exact test, the results prove
to be statistically significant, with a P value of
0.0009.
In both groups, discomfort was most evident 
in the myopic sub-group, with 22.2% of myopic 
patients in the pre-operative nepafenac 0.1% group 
experiencing some form of discomfort as opposed 
to 37.5% of myopes who were not given nepafenac 
0.1% pre-operatively. Furthermore, the greater the 
degree of myopia observed, the greater the degree 
of perceived discomfort. Least discomfort was 
evident in the hypermetropes, with discomfort 
evident in 2.6% of patients in the pre-operative 
NSAID subgroup and 4.3% of patients who were 
not given pre-operative nepafenac 0.1% (Figure 4). 
Irrespective of one’s refractive error, 
discomfort was most evident on insertion of the 
phaco-handpiece, amounting to 72.7% of all the 
discomfort felt throughout the cohort. Such a 
pattern was evident in all refractive error groups in 
both those patients treated with or without pre-
operative nepafenac 0.1%. Least discomfort was 
noted on insertion of the intra-ocular lens (IOL) 
(Figure 5). 
11
gOdRe Original Article 
 Malta Medical School Gazette  Volume 01 Issue 03 2017 
Figure 1: Graph showing the percentage of discomfort witnessed in each refractive error group in patients who 
were not given pre-operative topical NSAIDs. Discomfort being most evident in the myopic sub-group. 
 
Figure 2: Graph showing the percentage of discomfort witnessed in each refractive error group in 
patients who were given pre-operative topical NSAIDs. Discomfort being most evident in the myopic sub-group 
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Figure 3: Graph showing the percentage of discomfort witnessed in each refractive error group in patients who 
were given pre-operative topical NSAIDs vs those who were not given pre-operative NSAIDs. 
Figure 4: Graph showing the increase in discomfort witnessed with increasing myopic severity. 
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Figure 5: Graph showing the stage at which discomfort was witnessed within each refractive error group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no statistical correlation between 
patient age and perceived intra-operative 
discomfort. The same may be said for patient sex.  
 
Discussion 
Modern day cataract surgery is a quick, 
relatively painless and routine procedure, performed 
primarily under local anaesthetic.2 It involves 
extraction of the natural lens and replacing it with 
an artificial intra-ocular lens. The power of the 
artificial lens is calculated and adjusted pre-
operatively.3 Advances in cataract surgery have 
meant that this relatively routine procedure has 
come a very long way since the first recorded 
procedures in India in the 5th century BC.4 
Cataract surgery is today performed with the 
aid of phacoemulsification and is routinely 
performed under topical anaesthesia. Regional or 
local anaesthesia is also commonly employed, but 
recently comparative studies have shown equivalent 
results in intra-operative and post-operative pain 
relief.5 
Topical anaesthesia is commonly performed 
using ocular anaesthetics, Benoxinate 
(oxybuprocaine 0.4%) being the most commonly 
used due to its favorable side effect profile, being 
less toxic to the corneal epithelium when compared 
to amide anaesthetics such as lidocaine and 
bupivacaine. A study by S. Waheeb et.al showed 
that topical anesthesia solely using topical 
oxybuprocaine proved to be a safe alternative to 
retro- or peribulbar injections, being less time 
consuming and less risky.6 
Ocular inflammation is a common 
phenomenon during and after cataract surgery, 
resulting in intra-operative and postoperative pain. 
Topical NSAIDs reduce inflammation by reducing 
prostaglandin synthesis and have been shown to 
control and reduce inflammation after surgery.7 
Nepafenac 0.1% was used for the purpose of 
this study. Unlike other NSAIDs, nepafenac is 
unique in that it has a prodrug structure, making it a 
neutral molecule with rapid corneal permeability. 
The drug is rapidly hydrolyzed to amfenac, the 
active moiety of the drug. 7 It is understood that 
such conversion is targeted to the iris and ciliary 
body. Results from our study reveal that most 
discomfort is experienced on insertion of the phaco 
handpiece, the point at which there is a sudden 
surge in intra-ocular pressure and deepening of the 
anterior chamber, accompanied by stretching of the 
zonular fibers. We postulate that the targeted nature 
of nepafenac 0.1% helps in inhibiting or dampening 
the pain response felt when such events are set in 
motion.  
Our experience with pre-operative topical 
NSAIDs has been very encouraging, proving to be 
extremely beneficial in reducing intra-operative 
discomfort when compared to using topical 
oxybuprocaine alone. We postulate that such results 
are due inhibition of prostaglandin pathways that 
are immediately activated on manipulation of the 
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anterior chamber. 
It is interesting to note that most discomfort is 
witnessed in the myopic subgroup at all stages of 
the procedure. It is unclear as to why such a 
discrepancy is so evident, especially when one 
considers the larger nature of the anterior chamber 
in a myopic eye as opposed to a hypermetropic eye. 
We postulate that with advanced control of intra-
ocular pressure through active fluidics and an IOP 
ramp, one is able to reduce the overall discomfort 
observed during cataract surgery, especially when 
considering that over 70% of discomfort witnessed 
is on insertion of the phaco handpiece. The IOP 
ramp will allow a gradual and progressive increase 
in the IOP as opposed to a sudden surge in IOP 
during insertion of the phaco handpiece, resulting in 
a less sudden stretch of the anterior chamber.  
Our study is limited in that although strict 
exclusion and inclusion criteria were implemented, 
no efforts were made to introduce a control group or 
a means of blinding. A placebo would have proven 
beneficial, reducing both performance bias as well 
as observer bias from the surgeon involved. Whilst 
this ensures an adequate sample size for both 
groups of patients by being able to cater for drop 
outs, it does leave the door open to operator bias. 
That being said, data was collected over a relatively 
short period of time, not allowing for changes in 
operator technique over time, serving to counteract 
the Hawthorn effect. It is important to note that 
patients on any source of conflicting extraneous 
treatment such as any other pain relief medication 
were excluded for the purpose of this study. 
Furthermore, although the sample size used was 
substantial, it must be pointed out that no power 
calculation was performed in order to assess the 
true size of the sample needed. 
Conclusion 
Topical anesthesia is a satisfactory means of 
pain relief when undertaking phacoemulsification 
and IOL insertion. Furthermore, pre-operative 
topical NSAID application reduces discomfort rates 
in all refractive error subgroups. 
There is no association between patient age or 
sex and discomfort witnessed. 
It is evident that the greater the degree of 
myopia, the greater the rate of discomfort 
witnessed. Discomfort is also mostly witnessed on 
insertion of the phaco-handpiece, most prevalent in 
the myopic sub-group. 
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